Perseus Proteomics (TSE:4882) EBIT : 円-911.51 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Perseus Proteomics EBIT?

Perseus Proteomics's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was 円-245.25 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was 円-911.51 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Perseus Proteomics's annualized ROC % for the quarter that ended in Dec. 2023 was -938.24%. Perseus Proteomics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Perseus Proteomics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -31.60%.

Perseus Proteomics EBIT Historical Data

The historical data trend for Perseus Proteomics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perseus Proteomics EBIT Chart

Perseus Proteomics Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EBIT

Get a 7-Day Free Trial

-144.81

-812.40

-411.75

-472.20

-697.77

Perseus Proteomics Quarterly Data
	Mar18	Mar19	Dec19	Mar20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial												-169.07	-222.01	-234.57	-209.68	-245.25

Competitive Comparison of Perseus Proteomics's EBIT

For the Drug Manufacturers - General subindustry, Perseus Proteomics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Perseus Proteomics's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Perseus Proteomics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Perseus Proteomics's EV-to-EBIT falls into.

Perseus Proteomics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-911.51 Mil.

Perseus Proteomics (TSE:4882) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Perseus Proteomics's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-980.98 * ( 1 - -0.18% )	/	( (96.005	+	113.481)	/ 2 )
=	-982.745764	/	104.743
=	-938.24 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1989.786	-	43.714	-	( 1866.008	-	max(0, 96.856	-	1946.923	+	1866.008	))
=	96.005

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1796.664	-	28.997	-	( 1663.576	-	max(0, 99.615	-	1753.801	+	1663.576	))
=	113.481

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Perseus Proteomics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-980.98	/	( ( (0 + max(-15.941, 0))	+	(0 + max(-9.39, 0)) )	/	2 )
=	-980.98	/	( ( 0	+	0 )	/	2 )
=	-980.98	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(14.944	+	3.063	+	62.908)	-	(43.714	+	0	+	53.142)
=	-15.941

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(13.627	+	2.992	+	73.606)	-	(28.997	+	0	+	70.618)
=	-9.39

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Perseus Proteomics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-911.505	/	2884.173
	=	-31.60 %

Perseus Proteomics EBIT Related Terms

Thank you for viewing the detailed overview of Perseus Proteomics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Perseus Proteomics (TSE:4882) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Perseus Proteomics Inc (TSE:4882) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

4-7-6, Komaba, Tokyo Park Building, Meguro-ku, Tokyo, JPN, 153-0041

Website

https://www.ppmx.com

Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody based therapeutics and diagnostics drugs to cure against cancer and other diseases.

Perseus Proteomics (TSE:4882) Headlines

No Headlines